Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma

Journal of Clinical Oncology

Volumn 21, Issue 17, 2003, Pages 3343-3350

  Soiffer, Robert ^a   Hodi, F S ^a   Haluska, Frank ^a   Jung, Ken ^a   Gillessen, Silke ^a   Singer, Samuel ^a   Tanabe, Kenneth ^a   Duda, Rosemary ^a   Mentzer, Steven ^a   Jaklitsch, Michael ^a   Bueno, Raphael ^a   Clift, Shirley ^a   Hardy, Steve ^a   Neuberg, Donna ^a   Mulligan, Richard ^a   Webb, Iain ^a   Mihm, Martin ^a   Dranoff, Glenn ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELANOMA CELL VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER IMMUNIZATION; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; FOLLOW UP; HUMAN; LOCAL SKIN REACTION; MELANOMA; MELANOMA CELL; METASTASIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR IMMUNITY; VIRAL GENE DELIVERY SYSTEM; ADENOVIRUS; ADULT; AGED; AUTOTRANSPLANTATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC ENGINEERING; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

ADENOVIRIDAE; ADULT; AGED; CANCER VACCINES; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC ENGINEERING; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; HYPERSENSITIVITY, DELAYED; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0141576738     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.07.005     Document Type: Article

References (46)

1. Chen Y-T, Gure A, Tsang S, et al: Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci USA 95:6919-6923, 1998
2. Sahin U, Tureci O, Schmitt H, et al: Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92:11810-11813, 1995
3. Old L, Chen Y-T: New paths in human cancer serology. J Exp Med 187:1163-1167, 1998
4. Anichini A, Mortarini R, Maccalli C, et al: Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J Immunol 156:208-217, 1996
5. Boon T, van der Bruggen P: Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725-729, 1996
6. Romero P, Dunbar P, Valmori D, et al: Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 188:1641-1650, 1998
7. + T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-1 antibody production. Proc Natl Acad Sci USA 98:3964-3969, 2001
8. Jäger E, Nagata Y, Gnjatic S, et al: Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 97:4760-4765, 2000
9. Clark W, Elder D, Guerry D, et al: Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81:1893-1904, 1989
10. Clemente C, Mihm M, Bufalino R, et al: Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77:1303-1310, 1996
11. Mihm M, Clemente C, Cascinelli N: Tumor infiltrating lymphocytes in lymph node melanoma metastases: A histopathologic prognostic indicator and an expression of local immune response. Lab Invest 74:43-47, 1996
12. Mach N, Dranoff G: Cytokine-secreting tumor cell vaccines. Curr Opin Immunol 12:571-575, 2000
13. Jäger E, Jäger D, Knuth A: Clinical cancer vaccine trials. Curr Opin Immunol 14:178-182, 2002
14. Berd D, Murphy G, Maguire HC, et al: Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases. Cancer Res 51:2731-2734, 1991
15. Oratz R, Cockerill C, Speyer J, et al: Induction of tumor-infiltrating lymphocytes in human malignant melanoma metastases by immunization to melanoma antigen vaccine. J Biol Response Mod 8:355-358, 1989
16. Mitchell MS, Harel W, Kempf RA, et al: Active-specific immunotherapy for melanoma. J Clin Oncol 8:856-869, 1990
17. Hersey P: Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma. World J Surg 16:251-260, 1992
18. Morion DL, Foshag LJ, Hoon DSB, et al: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216:463-482, 1992
19. Slingluff C, Vollmer R, Siegler H: Stage II malignant melanoma: Presentation of a prognostic model and an assessment of specific active immunotherapy in 1,273 patients. J Surg Oncol 39:139-147, 1988
20. Livingston P, Wong G, Adluri S, et al: Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:1036-1044, 1994
21. Marchand M, van Baren N, Weynants P, et al: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 80:219-230, 1999
22. Jäger E, Bernhard H, Romero P, et al: Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma associated antigens. Int J Cancer 66:162-169, 1996
23. Nestle F, Alijagic S, Gilliet M, et al: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med 4:328-332, 1998
24. Rosenberg S, Yang J, Schwartzentruber D, et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med 4:321-327, 1998
25. Jäger E, Gnjatic S, Nagata Y, et al: Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 97:12198-12203, 2000
26. Wang F, Bade E, Kuniyoshi C, et al: Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res 5:2756-2765, 1999
27. Lee P, Wang F, Kuniyoshi J, et al: Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 19:3836-3847, 2001
28. Thumer B, Haendle I, Roder C, et al: Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669-1678, 1999
29. Banchereau J, Palucka AK, Dhodapkar M, et al: Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61:6451-6458, 2001
30. Slingluff CL Jr, Yamshchikov G, Neese P, et al: Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: Immunologic and clinical outcomes. Clin Cancer Res 7:3012-3024, 2001
31. Dranoff G, Jaffee E, Lazenby A, et al: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539-3543, 1993
32. Huang AY, Golumbek P, Ahmadzadeh M, et al: Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961-965, 1994
33. Mach N, Gillessen S, Wilson SB, et al: Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or flt3-ligand. Cancer Res 60:3239-3246, 2000
34. Reilly R, Machiels J-P, Emens L, et al: The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res 61:880-883, 2001
35. Soiffer R, Lynch T, Mihm M, et al: Vaccination with irradiated, autologous melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor generates potent anti-tumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 95:13141-13146, 1998
36. Mulligan RC: The basic science of gene therapy. Science 260:926-932, 1993
37. Shenk T: Adenoviridae: The viruses and their replication, in Fields BN, Knipe DM, Howley PM (eds): Fields Virology (ed 3). Philadelphia, PA, Lippincott-Raven Publishers, 1996, pp 2111-2148
38. Hardy S, Kitamura M, Harris-Stansil T, et al: Construction of adenovirus vectors through cre-lox recombination. J Virol 71:1842-1849, 1997
39. Cullen BR: Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism. Cell 46:973-982, 1986
40. Dranoff G, Soiffer R, Lynch T, et al: A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor. Hum Gene Ther 8:111-123, 1997
41. Murphy G, Bhan A, Sato S, et al: A new immunologic marker for human Langerhan cells. N Engl J Med 304:791-792, 1981
42. Salgia R, Lynch T, Skarin A, et al: Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 21:624-630, 2003
43. Schmollinger JC, Vonderheide RH, Hoar KM, et al: Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci U S A 100:3398-3403, 2003
44. Hodi FS, Mihm MC, Soiffer RJ, et al: Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100:4712-4717, 2003
45. Yu J, Burwick J, Dranoff G, et al: Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Hum Gene Ther 8:1065-1072, 1997
46. Borrello I, Sotomayor E, Cooke S, et al: A universal granulocyte- macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum Gene Ther 10:1983-1991, 1999